Radiomedix
RadioMedix, a Houston-based biotech firm, innovates targeted radiopharmaceuticals for cancer diagnosis and therapy.
Founded
2006RadioMedix, a Houston-based biotech firm, innovates targeted radiopharmaceuticals for cancer diagnosis and therapy.
RadioMedix, Inc., founded in Houston, Texas, is a clinical-stage biotechnology company dedicated to advancing the field of nuclear medicine. The company's core mission is to innovate targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of cancer. Their product portfolio includes PET imaging agents and therapeutic radiopharmaceuticals labeled with alpha and beta emitters. Additionally, RadioMedix offers CFR-compliant contract services for academic and industrial partners, aiming to enhance cancer treatment through precision medicine.
Notable figures associated with RadioMedix include its team of experienced scientists and industry experts who drive its research and development efforts. The company has made significant strides in the biotech sector, with key achievements including the development of novel radiopharmaceuticals that have progressed to clinical trials. RadioMedix's impact on the medical community is marked by its contributions to more effective cancer diagnostics and therapies, positioning it as a leader in the nuclear medicine landscape.
Companies similar to Radiomedix include Radionetics Oncology, Illumina Radiopharmaceuticals, RadioRx and Nucleus RadioPharma.
Radiomedix was founded in 2006.
Radiomedix's headquarters is located in Houston, TX, US.
Radiomedix's most recent funding round was for $40M (USD) in October 2022.
As of Oct 7, 2022, Radiomedix has raised a total of $40M (USD).
Radiomedix has 33 employees as of Feb 4, 2024.
RadioRx
radiorx.com
